NSE filing, NSE: SAROJA. Summary written from the filing by ALFA Finder's alert engine.
Saroja Pharma Industries India Ltd: key numbers
- Share price
- ₹38.80
- Market cap
- ₹15.60 Cr
- Revenue (annual)
- ₹70.13 Cr
- Net profit (annual)
- ₹1.62 Cr
- P/E (TTM)
- 9.6×Sector 34.1×
- Promoter holding
- 73.02%
- FII holding
- 0.00%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Saroja Pharma Industries India Ltd
All →Saroja Pharma Industries India Management Change
Saroja Pharma's statutory auditor Pravin Chandak & Associates resigned effective October 26, 2026, citing pre-occupation. The company will appoint new auditors to fill the vacancy.
Saroja Pharma Industries India Management Change
Mr. Ravindra Shivaji Salaskar has resigned as Whole-time Director of Saroja Pharma Industries India Limited, effective October 5, 2026. He continues as the company's CFO.
Saroja Pharma Industries India Annual General Meeting
Saroja Pharma Industries India Limited held its 8th Annual General Meeting on September 30, 2026, through video conferencing to transact business.
Saroja Pharma Industries India Management Change
Saroja Pharma Industries India Limited appointed Mr. Ravindra Shivaji Salaskar as Chief Financial Officer. He currently serves as a Whole-time Director of the company.
Saroja Pharma Industries India Annual General Meeting
Saroja Pharma Industries India Limited has issued a notice for its 8th Annual General Meeting, scheduled to be held on September 30, 2026, through video conferencing.
Saroja Pharma Industries India Board Meeting Outcome
Saroja Pharma Industries approved its draft Board Report, Management Discussion and Analysis Report, and the notice for its 8th Annual General Meeting.
Other board meeting outcome announcements
All →R R Kabel Board Meeting Outcome
RR Kabel's board approved amendments to its UPSI fair disclosure code on 28 October 2026. The amended code is enclosed and posted on the company website.
M K Exim (India) Board Meeting Outcome
M.K. Exim (India) approved shifting its registered office within Jaipur to Plot J-1247, Sitapura. The board meeting was held on October 28, 2026.
United Spirits Board Meeting Outcome
United Spirits' board approved amendments to its insider trading code on 28 October 2026, effective 29 October 2026. The revised code is available on the company website.
SBI Funds Management Board Meeting Outcome
SBI Funds Management extended internal auditor Chhajed & Doshi's term to March 31, 2030. This routine decision was taken at the October 28, 2026 board meeting.
- Execution
- April 1, 2028 to March 31, 2030
Paras Healthcare Board Meeting Outcome
Paras Healthcare filed its board-approved UPSI fair disclosure code under Regulation 8(2). This routine governance policy update reports no business event.
Gateway Distriparks Board Meeting Outcome
Gateway Distriparks' board approved a revised Code of Practices for Fair Disclosure of UPSI under PIT Regulation 8(2). This is a routine governance policy update with no business event.